Side effects From the digestive system : nausea, diarrhea, vomiting, abdominal pain, flatulence, anorexia. cholestatic jaundice (especially in patients with a history of liver disease), hepatitis, gepatonekroz.From the nervous system : dizziness, headache, fatigue, anxiety, tremor, insomnia, “nightmarish” dream, peripheral paralgeziya (anomaly perception of feeling pain), sweating , increased intracranial pressure, anxiety, confusion, depression, hallucinations, and other symptoms of psychotic reactions (sometimes progressing to states in which the patient may self-harm), migraine, syncope, thrombosis of the cerebral arteries..
From the senses : violation taste and smell, visual disturbances (diplopia, changes in color vision), tinnitus, hearing loss. From the femara: tachycardia, cardiac arrhythmias, lowering blood pressure, rush of blood to the skin. From the hematopoietic system : leukopenia, granulocytopenia, anemia, thrombocytopenia, leukocytosis, thrombocytosis, haemolytic anemia. From the laboratory parameters :. hypoprothrombinemia, increased activity of “liver” transaminases and alkaline phosphatase, hypercreatininemia, hyperbilirubinemia, hyperglycemia From the urinary system : hematuria, crystalluria (particularly in alkaline urine and low urine output), glomerulonephritis, dysuria, polyuria, urinary retention, albuminuria, urethral bleeding, hematuria, reduced azotvydelitelnoy renal function, interetitsialny nephritis. Allergic reactions : itching, rash, blisters, accompanied by bleeding, and small nodules, forming scabs, drug fever, petechial hemorrhages (petechiae), swelling of the face or throat, shortness of breath, eosinophilia, increased photosensitivity, vasculitis, nodular erythema, exudative erythema multiforme, Stevens-Johnson syndrome (malignant exudative erythema), toxic epidermal necrolysis (Lyell’s syndrome). Other : arthralgia, arthritis, tenosynovitis , tendon rupture, fatigue, myalgia, superinfection (candidiasis, pseudomembranous colitis).
- childhood femara and adolescence to 18 years;
- Hypersensitivity to ciprofloxacin and other drugs of fluoroquinolones group.
Patients with epilepsy, attacks of convulsions in the history of vascular disease and organic brain lesions due to the threat of adverse reactions from the ciprofloxacin should be used only for health reasons.
If you experience during or after treatment with ciprofloxacin severe and prolonged diarrhea should exclude the diagnosis pseudomembranous colitis, which requires immediate discontinuation of the drug and appropriate treatment.
if you experience pain in the tendons, or when the first signs of tenosynovitis treatment should be discontinued due to the fact that the described individual cases of inflammation and even rupture tendons during treatment with fluoroquinolones.
during treatment with ciprofloxacin necessary to ensure a sufficient amount of liquid under normal urine output.
during treatment with ciprofloxacin should avoid exposure to direct sunlight.
Effects on ability to drive vehicles and management mechanisms
Patients taking ciprofloxacin should be careful when driving and busy with other potentially hazardous activities that require increased attention and femara psychomotor speed reactions (especially with simultaneous use of alcohol).
With simultaneous use of ciprofloxacin with ddI absorption of ciprofloxacin is reduced due to the formation of complexes of ciprofloxacin with the contained didanosine aluminum and magnesium salts.
Simultaneous administration of ciprofloxacin and theophylline may increase theophylline plasma concentrations due to competitive inhibition in the binding sites of cytochrome femara, which increases the half-life of theophylline and increase the risk of toxic effects associated with theophylline.
Simultaneous administration of antacids and preparations containing aluminum ions, zinc, iron or magnesium, may cause a decrease in suction ciprofloxacin, so the interval between administration of these drugs should be not less than h.
At simultaneous application of ciprofloxacin and anticoagulants lengthened bleeding time.
In an application tsiprofoksatsina and cyclosporine nephrotoxicity intensified recently.